Vera Therapeutics (VERA) Invested Capital (2020 - 2026)

Vera Therapeutics has reported Invested Capital for 7 years, with the latest figure at $574.7 million in Q1 2026.

• For the quarter ending Q1 2026, Invested Capital fell 1.91% year-over-year to $574.7 million; the trailing twelve-month figure through Mar 2026 stood at $574.7 million (down 1.91% YoY), and the FY2025 full-year result was $679.4 million, up 8.21% from the prior year.
• Invested Capital for Q1 2026 stood at $574.7 million, down from $679.4 million in the prior quarter.
• The five-year high for Invested Capital was $679.4 million in Q4 2025, with the low at $101.7 million in Q4 2022.
• Historically, Invested Capital has averaged $337.2 million across 5 years, with a median of $339.5 million in 2024.
• Annual changes were most pronounced in 2024 — Invested Capital surged 314.25% — and 2026, when it slipped 1.91%.
• Vera Therapeutics' Invested Capital stood at $101.7 million in 2022, then surged by 49.0% to $151.6 million in 2023, then surged by 314.25% to $627.8 million in 2024, then increased by 8.21% to $679.4 million in 2025, then dropped by 15.4% to $574.7 million in 2026.
• The last three Invested Capital figures came in at $574.7 million (Q1 2026), $679.4 million (Q4 2025), and $473.5 million (Q3 2025), per Business Quant data.